PaxMedica is a clinical-stage biopharmaceutical company developing anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, including Autism Spectrum Disorder (ASD) and Fragile X-associated tremor/ataxia (FXTAS). Its lead programs include PAX-101, an intravenous suramin formulation for the treatment of the core symptoms of ASD, and PAX-102, a proprietary intranasal formulation of suramin.